Client: World’s leading generic company

The challenge

The client was reviewing its position in hospital oncology products in Europe. The question it faced was: should it invest in, or divest from this market? It was a difficult decision. Group Board executives were emotionally tied to the marketplace, and would be unlikely to shut down this part of the business. The company recognised that it needed external expertise to assess the situation objectively and recommend actions.

This was decision-making at the highest level, and the client needed experienced advisers: people who’d run a hospital business themselves and could empathise with their dilemma, but could also think laterally and point out opportunities.

Our approach

We undertook a detailed strategic review using Pharmawise Organic, a methodology we have developed that evolves with the pharma sector and gives a clear insight into the real opportunities in the marketplace.

This methodology is part of our core offer and ethos - if we don’t have the expertise to solve a client’s problem, we don’t take on the assignment. The fact that we do take on the sector’s most difficult challenges, and apply the kind of breakthrough thinking that enables clients to make the right decisions, proves the effectiveness of this approach.

Result

Our recommendations and actions led the client to stay in the hospital market. They have established a leading market share, with their own fully back-integrated production in some key products. The strategy has proved so successful that it has been rolled out globally, and the company now has leading positions in the USA and other markets.

‍

‍

‍